Construction Therapeutics’ optimistic part 2 information for aleniglipron despatched its inventory value hovering final 12 months.
The medication might be a part of the fast-growing weight reduction market, however it is going to face loads of competitors.
The clinical-stage biotech might see its shares plummet ought to there be any medical setback.
10 shares we like higher than Construction Therapeutics ›
Construction Therapeutics(NASDAQ: GPCR) ended 2025 on a powerful be aware. Shares of the clinical-stage biotech soared in December after it reported sturdy mid-stage information for its main pipeline candidate, an investigational weight reduction medication referred to as aleniglipron. If Construction Therapeutics could make extra progress towards coming into the fast-growing anti-obesity market this 12 months, we might see the corporate carrying the momentum it had final 12 months by 2026.
However can the inventory actually ship the sorts of returns it did final 12 months? And is it price investing in for these targeted on the lengthy recreation? Let’s discover out.
Picture supply: Getty Pictures.
Aleniglipron is a once-daily oral GLP-1 candidate. In a 36-week part 2b research, the medication posted a aggressive placebo-adjusted imply weight lack of 11.3% on the highest dose. In one other ongoing mid-stage research that includes even larger doses of the drug, investigators noticed a imply weight lack of as much as 15.3% after 36 weeks. There was a ten.4% discontinuation charge on account of adversarial reactions within the first research, however that is fairly frequent with GLP-1 medicines.
Total, tolerability was properly inside the norm for this class of medication. Primarily based on these outcomes, Construction Therapeutics plans to provoke a part 3 research for aleniglipron, seemingly this 12 months. Construction Therapeutics does produce other candidates in its pipeline. It not too long ago initiated a part 1 research for ACCG-2671, an oral weight reduction candidate that mimics the motion of the amylin hormone, which performs a job in regulating blood sugar and selling satiety; it’s more and more turning into a goal for drugmakers seeking to develop breakthrough anti-obesity medicines.
Aleniglipron nonetheless has a protracted strategy to go earlier than incomes regulatory approval. Within the meantime, it could encounter vital medical or regulatory hurdles. True, it’s taken orally, giving it a slight edge over a number of the main weight administration therapies in the marketplace, that are administered subcutaneously. Many sufferers will choose drugs over needles. And the previous are typically simpler to fabricate, retailer, and transport, permitting them to be offered at decrease costs.
Nonetheless, by the point aleniglipron will get to the market, there must be at the least two different oral medicines already permitted. The U.S. Meals and Drug Administration not too long ago permitted an oral formulation of Wegovy. Additionally it is reviewing an software for orforglipron, one other oral medication, this one developed by Eli Lilly.
Moreover, Novo Nordisk has a twin GLP-1 and amylin receptor agonist in part 3 research in each subcutaneous and oral formulations. In fact, what in the end issues most is efficacy — if aleniglipron proves simpler than these and different comparable weight reduction medicine, it is going to nonetheless carve out a stable area of interest for itself on this huge and rising market. Nonetheless, it is too early to know whether or not that is the case. That makes Construction Therapeutics’ shares considerably dangerous at this level.
It will likely be difficult for Construction Therapeutics to double once more this 12 months. With a market cap of $4.4 billion and no permitted product, some may even argue that the market has gotten forward of itself. The corporate’s early-stage research will not yield the sorts of outcomes that can considerably impression the inventory. Part 1 research are likely to give attention to security and tolerability in a small variety of sufferers. Testing efficacy comes within the later levels.
Nonetheless, Construction Therapeutics might be an honest acquisition goal for a big pharmaceutical chief seeking to enter the load loss area with out having to undertake the troublesome work of making novel medicines from scratch. Contemplating how rapidly the gross sales of weight administration medicine are rising, this would not be shocking in any respect. Nonetheless, long-term buyers should not financial institution on that taking place.
For my part, Construction Therapeutics is way too dangerous for many buyers, contemplating its shares might plummet on the mere sight of any medical setback. Buyers comfy with heightened volatility might wish to contemplate initiating a small place within the firm, because it has ample upside potential regardless of the chance. Nonetheless, risk-averse buyers ought to look elsewhere.
Before you purchase inventory in Construction Therapeutics, contemplate this:
The Motley Idiot Inventory Advisor analyst workforce simply recognized what they consider are the 10 greatest shares for buyers to purchase now… and Construction Therapeutics wasn’t one in every of them. The ten shares that made the minimize might produce monster returns within the coming years.
Think about when Netflix made this listing on December 17, 2004… in case you invested $1,000 on the time of our suggestion, you’d have $482,451!* Or when Nvidia made this listing on April 15, 2005… in case you invested $1,000 on the time of our suggestion, you’d have $1,133,229!*
Now, it’s price noting Inventory Advisor’s whole common return is 968% — a market-crushing outperformance in comparison with 197% for the S&P 500. Do not miss the newest prime 10 listing, accessible with Inventory Advisor, and be a part of an investing neighborhood constructed by particular person buyers for particular person buyers.
See the ten shares »
*Inventory Advisor returns as of January 11, 2026.
Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Idiot recommends Novo Nordisk. The Motley Idiot has a disclosure coverage.
Can This Inventory Double Once more in 2026? was initially printed by The Motley Idiot
